Teti A, Farina A R, Villanova I, Tiberio A, Tacconelli A, Sciortino G, Chambers A F, Gulino A, Mackay A R
Department of Experimental Medicine, University of L'Aquila, Coppito II, Italy.
Int J Cancer. 1998 Jul 3;77(1):82-93. doi: 10.1002/(sici)1097-0215(19980703)77:1<82::aid-ijc14>3.0.co;2-b.
We show that osteopontin (OPN), bone sialoprotein (BSP) and GRGDSP peptides, in solution, induce activation of metalloproteinase-2 (MMP-2) secreted by human GCT23 giant cell tumour cells. Activation of MMP-2 is RGD sequence dependent, possibly involves anti-alphaVbeta3 integrins, is preceded by a change from spread to rounded cell morphology and is mimicked by the actin depolymerising agent cytochalasin B. Cells that had spread on OPN, BSP and GRGDSP substrata failed to activate MMP-2, but subsequent addition of soluble GRGDSP induced rounding and MMP-2 activation. Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity. Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2. GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2. This was consistent with the possible relocation of constitutive MT-MMP-1 to the cell surface as a prerequisite for subsequent cell surface MMP-2/TIMP-2/MT-MMP-1 complex formation and to the potential induction of conditions favourable for reciprocal cell surface MMP-1/MMP-2 activation. Our data provide a novel insight into interactions between RGD containing bone matrices, GCT cells and MMPs of potential relevance to GCT pathology.
我们发现,骨桥蛋白(OPN)、骨唾液蛋白(BSP)和GRGDSP肽在溶液中可诱导人GCT23巨细胞瘤细胞分泌的金属蛋白酶-2(MMP-2)活化。MMP-2的活化依赖于RGD序列,可能涉及抗αVβ3整合素,在细胞形态从铺展变为圆形之前发生,并且可被肌动蛋白解聚剂细胞松弛素B模拟。在OPN、BSP和GRGDSP基质上铺展的细胞未能激活MMP-2,但随后添加可溶性GRGDSP会诱导细胞变圆并激活MMP-2。GRGDSP和细胞松弛素B诱导的活化是细胞介导的,可被EDTA、金属蛋白酶-2组织抑制剂(TIMP-2)和MMP-2羧基末端抑制,这与膜型(MT)-MMP的作用一致,但不涉及尿激酶、纤溶酶或凝血酶活性。GRGDSP和细胞松弛素B诱导的活化,但不是细胞变圆,可被赫曲霉素A、放线菌酮和放线菌素D抑制,提示酪氨酸激酶、蛋白质和RNA合成起作用,但与MT-MMP-1、MMP-1、MMP-2、TIMP-1或TIMP-2的mRNA变化无关。GRGDSP和细胞松弛素B提高了膜相关的前体和活性形式MMP-1和MMP-2的水平,但不包括MT-MMP-1,刺激了细胞表面MMP-1染色并诱导了MT-MMP-1、MMP-2和TIMP-2的染色。这与组成型MT-MMP-1可能重新定位到细胞表面作为随后细胞表面MMP-2/TIMP-2/MT-MMP-1复合物形成的先决条件以及对有利于相互细胞表面MMP-1/MMP-2活化的条件的潜在诱导一致。我们的数据为含RGD的骨基质、GCT细胞和MMP之间的相互作用提供了新的见解,这些相互作用可能与GCT病理学相关。